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Amongst the various routes of drug delivery, oral route is 
perhaps the most preferred to the patient and the 
clinicians. Based on our present understandings of 
biochemical and physiological aspects of absorption and 
metabolism, many drugs cannot be delivered 
successfully through the conventional oral route, because 
after administration the drugs are subjected to extensive 
pre- systemic clearance, which often leads to a lack of 
significant correlation between membrane permeability, 
absorption and bioavailability.1 
On the contrary of per oral route, mucosal layer (nasal, 
rectal, vaginal, ocular and oral cavity) are often 
considered as potential sites for drug administration and 
having distinct advantages for systemic drug delivery. 
These advantages include possible liver bypass effect, 
avoidance of presystemic elimination within the GI tract 
with improved absorption and hence better 
bioavailability.2 
The nasal cavity has been investigated as a site for 
systemic drug delivery but the potential irritation and the 
irreversible damage to the ciliary action of the nasal 
cavity from chronic application of nasal dosage, as well 
as the large intra- and inter-subject variability in mucus 
secretion in the nasal mucosa, could significantly affect 
drug absorption from this site. Even though the rectal, 
vaginal, and ocular mucosae all offer certain advantages, 
but the poor patient acceptability associated with these 
sites renders them reserved for local applications rather 
than systemic drug administration.3, 4, 5 The buccal route 
has the capability to maintain a delivery system at a 
particular position for an extended period of time 
therefore it has a great appeal for both local as well as 
systemic drug bioavailability. The buccal mucosa is 
relatively permeable with a rich blood supply and 
absorption occurring from this place is efficient, and 
additionally the route also provides rapid drug transport 
to the systemic circulation and avoids degradation by 
gastro-intestinal enzymes and first pass hepatic 
metabolism.6 
MUCOADHESIVE DRUG DELIVERY SYSTEM IN 
ORAL CAVITY: 
Drug delivery via the membranes of the oral cavity can 
be subdivided as follows: 
 Sublingual delivery: is systemic delivery of drug 
through the mucosal membranes lining the floor of 
the mouth. 
 Buccal delivery: is drug administration through the 
mucosal membranes lining the cheeks.  
 Local delivery: is drug delivery into the oral 
cavity.7 
ADVANTAGES OF BUCCAL DRUG DELIVERY 
SYSTEM
8, 9, 10, 11 
Bypass of the gastrointestinal tract and hepatic portal 
system, increasing the bioavailability of orally 
administered drugs that otherwise undergo hepatic first-
pass metabolism. In addition the drug is protected from 
degradation due to pH and digestive enzymes of the 
middle gastrointestinal tract. 
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1. Improved patient compliance due to the elimination 
of associated pain with injections. 
2. A relatively rapid onset of action can be achieved 
relative to the oral route. 
3. The formulation can be removed if therapy is 
required to be discontinued. 
4. Improve the performance of many drugs, as they are 
having prolonged contact time with the mucosa. 
5. The residence time of dosage form at the site of 
absorption is prolong, hence increases the 
bioavailability. 
6. High blood supply and good blood flow rate cause 
rapid absorption. 
7. It offers a passive system of drug absorption and 
does not require any activation. 
8. Significant cost reductions may be achieved and 
dose-related side effects may be reduced due to API 
localization at the disease site. 
DISADVANTAGES OF BUCCAL DRUG 
DELIVERY
12, 13, 14, 15
  
As compared to the sublingual membrane the buccal 
membrane has low permeability. 
1. Limited surface area is available for absorption. 
2. This route cannot administer drugs which irritate the 
mucosa or have a bitter or unpleasant taste or an 
obnoxious odour. 
3. This route is unacceptable for those drugs which are 
unstable at pH of buccal environment. 
4. The continuous secretion of the saliva (0.5-2 l/day) 
leads to subsequent dilution of the drug. 
5. Drugs with large dose are difficult to be 
administered. 
STRUCTURAL FEATURES OF ORAL CAVITY 
16, 
17, 18, 19 
The oral cavity consists of two regions: 
 Outer oral vestibule, which is bounded by cheeks, 
lips, teeth and gingival (gums). 
 Oral cavity proper, which extends from teeth and 
gums back to the fauces (which lead to pharynx) 





Figure 1: Anatomical structure of Oral Cavity 
 
OVERVIEW OF BUCCAL MUCOSA
  
Oral mucosa is divided into two parts:  
A. Epithelium: The epithelium, as a protective layer 
for the tissues beneath, is divided into: 
(a) non-keratinized surface in the mucosal lining of the 
soft palate, the ventral surface of the tongue, the 
floor of the mouth, alveolar mucosa, vestibule, lips, 
and cheeks. 
(b) Keratinized epithelium which is found in the hard 
palate and non-flexible regions of the oral cavity. 
B. Basement membrane and connective tissue: 
Basement membrane is a boundary between the 
basal layer of epithelium and connective tissue. It 
consists of extracellular materials. The organisation 
which determines the mechanical stability, 
resistance to deformation, extendibility of tissue is 
made up of bulk of connective tissue.  
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Figure 2: Structure of Buccal Mucosa 
 
The Mucus Layer: 
14 Mucus is a translucent and viscid 
secretion which forms a thin, continuous gel blanket 
adherent to the mucosal epithelial surface. The mean 
thickness of this layer varies from about 50 to 450 µm in 
humans. It is secreted by the goblet cells lining the 
epithelia or by special exocrine glands with mucus cells 
acini. The exact composition of the mucus layer varies 
substantially depending on the species, the anatomical 
location and the pathophysiological state.  However, it 
has the following general composition: 
1. Water - 95%  
2. Glycoproteins and Lipids - 0.5 to 5%  
3. Mineral salts - 0.5 to 1%  
4. Free Proteins - 0.5 to 1%  
Functions of mucus layer: 
20 
 Mucus layer is protective in nature because of its 
hydrophobocity. 
 Mucus layer acts as a barrier in tissue absorption of 
drugs and other substrates. 
 Mucus has strong adhesion properties and firmly 
binds to the epithelial cell surface as a continuous 
gel layer. 
 An important role of mucus layer is to lubricate the 
mucosal membrane and keep it moist. 
Permeability: 
It is estimated that the permeability of the buccal mucosa 
is 4-4000 times greater than the skin.21There are 
considerable differences in permeability between 
different region of the oral cavity because of diverse 
structures and functions of the different oral mucosa. . In 
general, the permeabilities of the oral mucosae decrease 
in the order of sublingual greater than buccal and buccal 
greater than palatal.1 This rank order is based on the 
relative thickness and degree of keratinization of these 
tissues, with the sublingual mucosa being relatively thin 
and non-keratinized, the buccal thicker and non-
keratinized, and the palatal intermediate in thickness but 
keratinized.  
The permeability barrier property of the oral mucosa is 
predominantly due to intracellular materials derived from 
the so called – “membrane coating granules” (MCGS).22 
Passive diffusion is the primary mechanism for the 
transport of drugs across the buccal mucosa, carrier 
mediated transport has been reported to have a small 
role. In buccal mucosa two routes of passive transport 
are found: 
Paracellular: involves the transport of compounds 
through the intercellular space between the cells. 
Transcellular: involves passage into and across the 
cells.4, 23 
 
Figure 3: Mechanism of Drug Transport 
Environment: 
7 
The oral cavity is marked by the presence of saliva 
produced by the salivary glands and mucus which is 
secreted by the major and minor salivary glands as part 
of saliva. Saliva is the protective fluid for all tissues of 
the oral cavity. It protects the soft tissues from abrasion 
by rough materials and from chemicals. The daily 
salivary volume is between 0.5 to 2 liters and it is this 
amount of fluid that is available to hydrate oral mucosal 
dosage forms. The main reason behind the selection of 
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hydrophilic polymeric matrices as vehicles for oral 
transmucosal drug delivery systems is this water rich 
environment of the oral cavity.  
Role of Saliva: 
24 
 Protective fluid for all tissues of the oral cavity. 
 Continuous mineralization / demineralization of the 
tooth enamel. 
 To hydrate oral mucosal dosage forms. 
Mucoadhesivity: 
25 
For the development of Buccal drug delivery systems, 
mucoadhesion of the device is a key element. For proper 
and good mucoadhesion, mucoadhesive polymer have 
been utilized in many different dosages forms such as 
tablets, patches, tapes, films, semisolids and powders. 
Addition of various polymers to drug delivery systems 
such as gums, increased the duration of attachment of the 
formulations to the mucous surface and also increased 
the efficacy. To serve as mucoadhesive polymers, the 
polymers should possess some general physiochemical 
features such as: 
o Predominantly anionic hydrophilicity with numerous 
hydrogen bond-forming groups. 
o Polymer and its degradation products should be non-
toxic, non-irritant and free from leachable 
impurities. 
o Good spreadability, wetting, swelling and solubility 
and biodegradability properties. 
o pH should be biocompatible and should possess 
good viscoelastic properties. 
o Should possess peel, tensile and shear strengths at 
the bioadhesive range.  
NOVEL BUCCAL DOSAGE FORMS
26, 27
  
The novel type buccal dosage forms include buccal 
adhesive tablets, patches, films, semisolids (ointments 
and gels) and powders.   
A. Buccal mucoadhesive tablets: Buccal 
mucoadhesive tablets are dry dosage forms that have 
to be moistened prior to placing in contact with 
buccal mucosa. They can deliver drug multi- 
directionally into the oral cavity or to the mucosal 
surface.    
B. Patches and Films: Buccal patches consists of two 
laminates or multilayered thin film that are round or 
oval in shape, consisting basically of adhesive 
polymeric layer and impermeable backing layer to 
provide unidirectional flow of drug across buccal 
mucosa. 
C. Semisolid Preparations (Ointments and Gels): 
Bioadhesive gels or ointments have less patient 
acceptability than solid bioadhesive dosage forms, 
and most of the dosage forms are used only for 
localized drug therapy within the oral cavity.  
D. Powders: Buccal bioadhesive powder dosage forms 
are a mixture of bioadhesive polymers and the drug 
and are sprayed onto the buccal mucosa  
BUCCAL ABSORPTION 
Buccal absorption leads systemic or local action via 
buccal mucosa.   
Mechanism of buccal absorption: Buccal drug 
absorption occurs by passive diffusion of the nonionized 
species. Passive diffusion is a process governed 
primarily by a concentration gradient, through the 
intercellular spaces of the epithelium. The passive 
transport of non-ionic species across the lipid membrane 
of the buccal cavity is the primary transport mechanism. 
The buccal mucosa has been said to be a lipoidal barrier 
to the passage of drugs, as is the case with many other 
mucosal membrane and the more lipophilic the drug 
molecule, the more readily it is absorbed.28 The dynamics 
of buccal absorption of drugs could be adequately 
described by first order rate process. Several potential 
barriers to buccal drug absorption have been identified. 
Dearden and Tomlison (1971) pointed out that salivary 
secretion alters the buccal absorption kinetics from drug 
solution by changing the concentration of drug in the 
mouth. The linear relationship between salivary secretion 
and time is given as follows: 
- dm/dt = Kc/ViVt 
Where, M - Mass of drug in mouth at time ıtı K - 
Proportionality constant C - Concentration of drug in 
mouth at time Vi - The volume of solution put into 
mouth cavity and Vt - Salivary secretion rate   
Factors affecting buccal absorption: The oral cavity is 
a complex environment for drug delivery as there are 
many interdependent and independent factors which 
reduce the absorbable concentration at the site of 
absorption.29, 30   
1. Membrane Factors: This involves degree of 
keratinization, surface area available for absorption, 
mucus layer of salivary pellicle, intercellular lipids of 
epithelium, basement membrane and lamina propria. In 
addition, the absorptive membrane thickness, blood 
supply/ lymph drainage, cell renewal and enzyme 
content will all contribute to reducing the rate and 
amount of drug entering the systemic circulation.     
2. Environmental Factors: 
A. Saliva: The thin film of saliva coats throughout the 
lining of buccal mucosa and is called salivary pellicle or 
film. The thickness of salivary film is 0.07 to 0.10 mm. 
The thickness, composition and movement of this film 
affect the rate of buccal absorption.   
B. Salivary glands: The minor salivary glands are 
located in epithelial or deep epithelial region of buccal 
mucosa. They constantly secrete mucus on surface of 
buccal mucosa. Although, mucus helps to retain 
mucoadhesive dosage forms, it is potential barrier to 
drug penetration.   
C. Movement of buccal tissues: Buccal region of oral 
cavity shows less active movements. The mucoadhesive 
polymers are to be incorporated to keep dosage form at 
buccal region for long periods to withstand tissue 
movements during talking and if possible during eating 




The term bioadhesion refers to any bond formed between 
two biological surfaces or a bond between a biological 
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and a synthetic surface. In the case of bioadhesive drug 
delivery systems, it is a bond formed between polymers 
and soft tissues. If the bond is formed between mucus 
and polymer, it is described as mucoadhesion.  Although 
the target of many bioadhesive delivery systems may be 
a soft tissue cell layer (i.e. epithelial cells), the actual 
adhesive bond may form with either the cell layer, a 
mucous layer or a combination of the two. In instances in 
which bonds form between mucus and polymer, the term 
mucoadhesion is used synonymously with bioadhesion. 
In general, bioadhesion is an all-inclusive term used to 
describe adhesive interactions with any biological or 
biologically derived substance, and mucoadhesion is 
used only when describing a bond involving mucus or a 
mucosal surface. 
Mechanism of Mucosal Adhesion
33, 34, 35, 36 
Several theories purposed the mechanism of 
mucoadhesion by the interaction of polymer and mucus. 
The mechanism of mucoadhesion is divided into two 
steps, first is contact step and second is consolidation 
step. In the first step the mucus layer come in contact 
with mucoadhesive and mucous membrane and the 
formulation swell and spread over mucus membrane. In 
the second consolidation step the moisture activates the 
mucoadhesive material, this plasticizes the system, this 
allow to mucoadhesive molecules to break free and link 
up by weak Vander walls and hydrogen bonds. The 
diffusion and dehydration theory explain the 
consolidation step.   
The diffusion theory is the mutually interacting of 
mucoadhesive molecules and glycoprotein of mucus and 
building of secondary bonds by interpenetration of their 
chains. 
 
Figure 4: Two steps of Mucoadhesion Process 
According to the dehydration theory the material get 
gelify when it come in contact with the mucus in the 
aqueous environment. The drawing of water into the 
formulation due to concentration gradient until the 
osmotic balance is reached. This process increases the 
contact time of mucous membrane with the mixture of 
formulation and mucus. So it is not the interpenetration 
of macromolecules chains, it is the water motion that 
lead to the consolidation of the adhesive bond. The 
dehydration theory is not applicable for highly hydrated 
forms or solid formulations.  
THEORIES OF MUCOADHESION
 
i) The Electronic Theory:  According to this theory, 
electron transfer occurs upon contact of an adhesive 
polymer with a mucus glycoprotein network because of 
differences in their electronic structures. This results in 
the formation of an electrical double layer at the 
interface. Adhesion occurs due to attractive forces across 
the double layer. 
ii) The Adsorption Theory:  According to this theory, 
after an initial contact between two surfaces, the material 
adheres because of surface forces acting between the 
atoms in the two surfaces. Two types of chemical bonds 
resulting from these forces are: 
 Primary chemical bonds of covalent nature.  
 Secondary chemical bonds having many different 
forces of attraction including electrostatic forces, 
Vander Waals forces, and hydrogen and 
hydrophobic bonds. 14, 37 
iii) The Wetting Theory
24, 33, 35
:  This theory applies to 
those liquid systems which present affinity to the surface 
in order to spread over it. The contact angle is a 
measuring technique used to find the affinity. It is a 
general rule that greater be the affinity lower the contact 
angle. For the adequate speadability the contact angle 
must be equal or close to zero. The spreadability 
coefficient (SAB) is calculated by the equation:  
SAB = γB- γA – γAB 
Where: γB is Surface energy and γA is Interfacial energy 
If greater the interfacial energy in relating to the 
individual surface energy, greater the adhesion work 
WA, i.e., greater the energy needed to separate the two 
phases.  
WA = γA + γB – Γab 
iv) The Diffusion Theory:  According to this theory the 
polymer chains and the mucus mix to a sufficient depth 
to create a semi permanent adhesive bond. The exact 
depth to which the polymer chains penetrate the mucus 
depends on the diffusion coefficient and the time of 
contact. This diffusion coefficient, in turn, depends on 
the value of molecular weight between cross-links and 
decreases significantly as the linking density increases. 
v) The Fracture Theory: For measurement of the 
mucoadhesion mechanism this is most studied theory. 
This theory is related to separation of two surfaces after 
adhesion. The fracture strength is equivalent to adhesive 
strength as given by  
G = (Eε / L) ½. 
Where: E is Young’s modules of elasticity, ε is Fracture 
energy and L is Critical crack length when two surfaces 




Buccal patch is a non dissolving thin matrix modified-
release dosage form. The patch is composed of one or 
more polymer films or layers containing the drug and/or 
other excipients. The patch may contain a mucoadhesive 
Kaur et al                                        Journal of Drug Delivery & Therapeutics; 2014, 4(3), 69-79 74 
 
© 2011-14, JDDT. All Rights Reserved                                                 ISSN: 2250-1177                                               CODEN (USA): JDDTAO 
polymer layer which bonds to the oral mucosa, gingiva, 
or teeth for controlled release of the drug into the oral 
mucosa (unidirectional release), oral cavity 
(unidirectional release), or both (bidirectional release). 
The patch is removed from the mouth and disposed of 
after a specified time. 
TYPES OF BCCCAL PATCHES
20, 35, 39 
a) Matrix type (Bi-directional): The buccal patch 
designed in a matrix configuration contains drug, 
adhesive, and additives mixed together. Bi-
directional patches release drug in both the mucosa 
and the mouth. 
b) Reservoir type (Unidirectional): The buccal patch 
designed in a reservoir system contains a cavity for 
the drug and additives separate from the adhesive. 
An impermeable backing is applied to control the 
direction of drug delivery; to reduce patch 
deformation and disintegration while in the mouth; 
and to prevent drug loss. Basically unidirectional 
types of buccal patches are used for drug delivery in 
the buccal cavity for local as well as systemic effect.  
 
Figure 5: Matrix and Reservoir type Buccal Patches 
Characteristics of an Ideal Buccal Patch
6, 40 
An ideal buccal adhesive system should possess the 
following characteristics:   
1) Quick adherence to the buccal mucosa and adequate 
mechanical strength.  
2) Should release the drug in a controlled fashion.   
3) Should facilitate the rate and extent of drug 
absorption.   
4) Should possess good patient compliance.   
5) Should not hinder normal functions such as talking, 
eating and drinking.   
6) Should accomplish unidirectional release of drug 
towards the mucosa.   
7) Should not aid in development of secondary infections 
such as dental caries.   
8) Should possess a wide margin of safety both locally 
and systemically.   
9) Should have good resistance to the flushing action of 
saliva. 
COMPOSITION OF BUCCAL PATCHES: 
The basic components of buccal bioadhesive drug 
delivery system are: 
1. Active Pharmaceutical Ingredient  
2. Mucoadhesive polymers  
3. Backing membrane  
4. Penetration enhancers  
5. Plasticizers  
1. ACTIVE PHARMACEUTICAL INGREDIENT 
(API): For buccal drug delivery, it is important to 
prolong and increase the contact between API and 
mucosa to obtain the desired therapeutic effect. The 
important drug properties that affect its diffusion through 
the patch as well as the buccal mucosa include molecular 
weight, chemical functionality and melting point.40 
The selection of a suitable drug for design of buccal 
mucoadhesive drug delivery system should be based on 
following characteristics41: 
 The conventional single dose of the drug should be 
low.  
 The drugs having biological half-life between 2-8 
hours are good candidates for controlled drug 
delivery.    
 The drug absorption should be passive when given 
orally. 
 Drug should not have bad taste and be free from 
irritancy, allergenicity and discoloration or erosion 
of teeth. 
2. MUCOADHESIVE POLYMERS: Mucoadhesives 
are synthetic or natural polymers that interact with the 
mucus layer covering the mucosal epithelial surface and 
main molecules constituting a major part of mucus.40 
The first step in the development of mucoadhesive 
dosage forms is the selection and characterization of 
appropriate mucoadhesive polymers in the formulation. 
Polymers are also used in matrix devices in which the 
drug is embedded in the polymer matrix, which controls 
the duration of release of drugs.  
Characteristics of Ideal Mucoadhesive Polymers
42, 43
: 
An ideal polymer for mucoadhesive drug delivery system 
should have the following characteristics:- 
 The polymer and its degradation products should be 
non-toxic and non-absorbable from the GIT. 
 It should be non-irritant to the mucus membrane. 
 It should preferably form a strong non-covalent 
bond with the mucin epithelial cell surfaces. 
 It should adhere quickly to moist tissue surface and 
should possess some site specificity. 
 It should allow easy incorporation of the drug and 
offer no hindrance to its release. 
 The polymer must not decompose on storage or 
during the shelf life of the dosage form. 
 The polymer should be easily available in the market 
and economical. 
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Table 1: Mucoadhesive Polymers for Buccal Patches
18, 40, 44 
CRITERIA CATEGORY EXAMPLES 
Source Semi-Natural/Natural 
 
Synthetic              
Agarose, Chitosan, Gelatine, Hyaluronic acid, Various gums (guar, hakea, 
xanthan, gellan, carragenan, pectin and sodium alginate) 
Cellulose derivatives 
CMC, Thiolated CMC, Sodium CMC, HEC, HPC, HPMC, MC, Methyl 
hydroxyl ethyl cellulose. 
Poly(acrylic acid)-based polymers 
CP, PC, PAA, Polyacrylates, Poly(methylvinylether-co-methacrylic acid), 
Poly (2-hydroxyethylmethacrylate), Poly (acrylicacid-co-
ethylhexylacrylate), Poly (methacrylte), 
Poly(alkylcyanoacrylate),Poly(isohexylcyanoacrylate), Poly 
(isobutylcyanoacrylate), Copolymer of acrylic acid and PEG 
Others 






CP, HEC, HPC (water < 38ºC), HPMC (cold water), PAA, sodium CMC, 
Sodium alginate, Chitosan (soluble in dilute aqueous acids), EC, PC 





Aminodextran, chitosan, dimethylaminoethyl-dextran, trimethylated 
chitosan 
Chitosan-EDTA, CP, CMC, pectin, PAA, PC, sodium alginate, sodium 
CMC, xanthan gum 







Electrostatic interaction  
Cyanoacrylate 




3. BACKING MEMBRANE: Backing membrane plays 
a major role in the attachment of bioadhesive devices to 
the mucus membrane. The materials used as backing 
membrane should be inert, and impermeable to the drug 
and penetration enhancer. The commonly used materials 
in backing membrane include carbopol, magnesium 
separate, HPMC, HPC, CMC, polycarbophil etc.26   
4. PENETRATION ENHANCERS: Substances that 
facilitate the permeation through buccal mucosa are 
referred as permeation enhancers. One of the major 
disadvantages associated with buccal drug delivery is the 
low flux of drugs across the mucosal epithelium, which 
results in low drug bioavailability. Various compounds 
have been investigated for their use as buccal penetration 
and absorption enhancers to increase the flux of drugs 
through the mucosa.20 
Mechanisms of Action of Permeation Enhancers
4, 45
:  
Mechanisms by which penetration enhancers are thought 
to improve mucosal absorption are as follows:  
a. Changing mucus rheology: Mucus forms 
viscoelastic layer of varying thickness that affects 
drug absorption. Further, saliva covering the mucus 
layers also hinders the absorption. Some permeation 
enhancers' act by reducing the viscosity of the 
mucus and saliva overcomes this barrier.  
b. Increasing the fluidity of lipid bilayer membrane: 
The most accepted mechanism of drug absorption 
through buccal mucosa is intracellular route. Some 
enhancers disturb the intracellular lipid packing by 
interaction with either lipid packing by interaction 
with either lipid or protein components.  
c. Acting on the components at tight junctions: 
Some enhancers act on desmosomes, a major 
component at the tight junctions thereby increases 
drug absorption.  
d. By overcoming the enzymatic barrier: These act 
by inhibiting the various peptidases and proteases 
present within buccal mucosa, thereby overcoming 
the enzymatic barrier. In addition, changes in 
membrane fluidity also alter the enzymatic activity 
indirectly.  
e. Increasing the thermodynamic activity of drugs: 
Some enhancers increase the solubility of drug there 
by alters the partition coefficient. This leads to 
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Sodium  lauryl sulfate, Sodium  laurate, Polyoxyethylene-20-cetyl ether,Laureth-9, 
Sodium dodecyl sulfate(SDS), Dioctyl Sodium sulfosuccinate 
Non-ionic 
Polyoxyethylene-9-lauryl ether, Tween 80, Nonylphenoxypolyoxyethylene, 
Polysorbates, Sodium glycolate. 
Bile Salts and Derivatives  Sodium deoxycholate, Sodium taurocholate, Sodium taurodihydrofusidate, Sodium 
glycodihydrofusidate, Sodium glycocholate, Sodium deoxycholate. 
Fatty acids and derivatives  Oleic acid, Caprylic acid, Mono(di)glycerides, Lauric acid, Linoleic acid, Acylcholines, 
Acylcarnitine, Sodium caprate. 
Chelating Agents  EDTA, Citric acid, Salicylates. 
Sulfoxides  Dimethyl sulfoxide(DMSO), Decylmethyl sulfoxide 
Polyols  Propylene glycol, Polyethylene glycol, Glycerol, Propanediol. 
Monohydric Alcohols  Ethanol, Isopropanol. 
Others  Urea and derivative, Unsaturated cyclic urea, Azone (1- dodecylazacycloheptan-2-one), 
Cyclodextrin, Enamine derivatives, Terpenes, Liposomes, Acyl carnitines and cholines. 
 
6. Plasticizers: These are the materials used to achieve 
softness and flexibility of thin films of polymer or 
blend of polymers. Examples of common 
plasticizers used are glycerol, propylene glycol, PEG 
200, PEG 400, castor oil etc. The plasticizers help in 
release of the drug substance from the polymer base 
as well as act as penetration enhancers. The choice 
of the plasticizer depends upon the ability of 
plasticizer material to solvate the polymer and alters 
the polymer- polymer interactions. When used in 
correct proportion to the polymer, these materials 
impart flexibility by relieving the molecular 
rigidity.26 
PREPARATION OF MUCOADHESIVE PATCHES 
Mucoadhesive buccal patches can be prepared by the 
following methods:  
1. Solvent casting: In this method, all ingredients are 
weighed accurately and mixed in pestle and mortal. Then 
the mixture is added gradually to magnetically stir 
solvent system, which contains the plasticizer. The 
stirring is continued until a clear solution is obtained. 
The solution is then transferred quantitatively to petri-
dish. The petri-dish is covered with inverted funnels to 
allow evaporation of the solvents46, 47. These are kept at 
20-25ºC temperature for 24 to 48 hours depending upon 
the solvent system used. After solvent evaporation a thin 
layer of the protective backing material is laminated onto 
the sheet of coated release liner to form a laminate that is 
die-cut to form patches of the desired size and 
geometry.48 
2. Direct milling: In this, patches are manufactured 
without the use of solvents. Drug and excipients are 
mechanically mixed by direct milling or by kneading, 
usually without the presence of any liquids. After the 
mixing process, the resultant material is rolled on a 
release liner until the desired thickness is achieved. The 
backing material is then laminated onto the sheet of 
coated release liner to form a laminate that is die-cut to 
form patches of the desired size and geometry.49 
EVALUATION OF BUCCAL PATCHES 
The following tests are used to evaluate the Buccal 
Patches: 
1. Weight uniformity: Five different randomly 
selected patches from each batch are weighed and 
the weight variation is calculated. 
2. Thickness uniformity: The thickness of each patch 
is measured by using digital vernier callipers at five 
different positions of the patch and the average is 
calculated. 
3. Folding Endurance: The folding endurance of each 
patch is determined by repeatedly folding the patch 
at the same place till it is broken or folded up to 300 
times, which is considered satisfactory to reveal 
good film properties.50  
4. Surface pH: The prepared buccal patches are left to 
swell for 2 hrs on the surface of an agar plate, 
prepared by dissolving 2% (w/v) agar in warm 
phosphate buffer of pH 6.8 under stirring and then 
pouring the solution into a Petri dish till gelling at 
room temperature.51 The surface pH is determined 
by placing pH paper on the surface of the swollen 
patch. The mean of three readings is recorded.52 
5. Drug content uniformity: For drug content 
uniformity, a 3 cm patch (without backing 
membrane) is separately dissolved in 100 ml of 
ethanol and simulated saliva solution (pH 6.2) 
mixture (20:80) for 12 h under occasional shaking. 
The resultant solution is filtered and the drug content 
of is estimated spectrophotometrically. The averages 
of three determinations are taken.53 
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6. Swelling Index: Buccal patches are weighed 
individually (W1) and placed separately in petri 
dishes containing phosphate buffer pH 6.8. The 
patches are removed from the petri dishes and 
excess surface water is removed using filter paper. 
The patches are reweighed (W2) and swelling index 
(SI) is calculated as follows: 54, 55 
SI = (W2-W1)/W1 
7. Moisture Content and moisture absorption56: The 
buccal patches are weighed accurately and kept in 
dessicator containing anhydrous calcium chloride. 
After 3 days, the patches are taken out and 
weighed12. The moisture content (%) is determined 
by calculating moisture loss (%) using the formula:  
 
Moisture content (%) = Initial weight - Final weightx100 
                              Final weight 
 
The buccal patches are weighed accurately and placed in 
a dessicator containing 100 ml of saturated solution of 
aluminium chloride, which maintains 76% and 86% 
humidity (RH). After 3 days, films are taken out and 
weighed. The moisture absorption is calculated using the 
formula: 
Moisture absorption (%) = Final weight-Initial weightx100 
                                                Initial weight 
 
8. In-vitro drug release: The United States 
Pharmacopeia (USP) XXIII-B rotating paddle 
method is used to study the drug release from the 
bilayered and multilayered patches. The dissolution 
medium consisted of phosphate buffer pH 6.8. The 
release is performed at 37°C ± 0.5°C, with a rotation 
speed of 50 rpm. The backing layer of buccal patch 
is attached to the glass disk with instant adhesive 
material. The disk is allocated to the bottom of the 
dissolution vessel. Samples (5 ml) are withdrawn at 
predetermined time intervals and replaced with fresh 
medium. The samples are then filtered through 
wattman filter paper and analyzed for drug content 
after appropriate dilution.57 
9. Ex-vivo mucoadhesion time: The ex-vivo 
mucoadhesion (residence) time is determined by 
locally modified USP disintegration apparatus using 
800 mL of simulated saliva (pH 6.2) and the 
temperature is maintained at (37±1) °C. A porcine 
buccal mucosa obtained from local slaughter house 
within 2 h of slaughter is used to mimic the human 
buccal mucosa in the in-vivo conditions. The 
mucosal membrane is carefully separated by 
removing the underlying connective tissues using 
surgical scissors. The separated mucosal membrane 
is washed with deionized water and then with 
simulated saliva (pH 6.2).58 Porcine buccal mucosa 
(3 cm diameter) is glued on the surface of a glass 
slab. One side of the buccal patch is hydrated with 
one drop of simulated saliva (pH 6.2) and brought 
into contact with porcine buccal mucosa by gentle 
pressing with a fingertip for few seconds. The glass 
slab is vertically fixed to the shaft of the 
disintegration apparatus and allowed to move up and 
down (25 cycles per min). The patch is completely 
immersed in simulated saliva at the lowest point and 
is out of the solution at the highest point. The time 
of complete erosion or detachment of the patch from 
the mucosal surface is recorded as ex-vivo 
mucoadhesion time.59  
10. Ex-vivo mucoadhesive strength: The force 
required to detach the attachment of mucoadhesive 
film from the mucosal surface was applied as a 
measure of the mucoadhesive strength. This study 
was carried out on a specially fabricated physical 
balance assembly. Porcine buccal mucosa was glued 
on a dry petri dish surface by placing the mucosal 
surface outward and it was moistened with few 
drops of simulated saliva (pH 6.2). The right side 
pan of the balance was replaced by a glass disc 
glued with a buccal patch of 3 cm diameter. The 
balance was adjusted for equal oscillation by 
keeping sufficient weight on the left pan. A weight 
of 5 g (w1) was removed from the left pan, which 
lowered the pan and buccal patch was brought in 
contact with pre moistened mucosa for 5 min. Then 
weights were increased gently on the left pan until 
the attachment breaks (w2). The difference in weight 
(w2-w1) was taken as mucoadhesive strength.
59 The 
mucoadhesive force was calculated from the 
following equation: 
Mucoadhesive force (kg/m/s) =  
Mucoadhesive strength (g) x acceleration due to gravity 
   1000 
     Here, acceleration due to gravity 9.8 m/s−1 
11. Ex-vivo permeation study: The ex-vivo buccal 
permeation through the porcine buccal mucosa is 
performed using a modified Franz glass diffusion 
cell. Porcine buccal mucosa is obtained from a local 
slaughterhouse and used within 2 h of slaughter. 
Freshly obtained porcine buccal mucosa is mounted 
between the donor and receptor compartments. The 
patch is placed on the smooth surface of mucosa by 
gentle pressing and the compartments are clamped 
together. The donor compartment is moistened with 
1 ml of simulated saliva (pH 6.2) and the receptor 
compartment is filled to touch the membrane with a 
mixture of 100 ml of ethanol and isotonic phosphate 
buffer (20:80).60, 61 The fluid motion in the receptor 
compartment is maintained by stirring with a 
magnetic bead at 50 rpm. The temperature is 
maintained at (37±0.2) °C by water jacket 
surrounding the chamber. At predetermined time 
intervals, a 2 ml sample is withdrawn (replaced with 
fresh medium) and analyzed spectrophotometrically. 
The permeation study is performed in triplicate. 
12. Stability Studies in Human Saliva62: The stability 
study of buccal patches is performed in natural 
human saliva. The human saliva is collected from 
humans (age 18-50 years). Buccal patches are placed 
in separate Petri dishes containing 5 ml of human 
saliva and placed in a temperature-controlled oven at 
37°C ± 0.2°C for 6 hours. At regular time intervals 
(0, 1, 2, 3, and 6 hours), the patches are examined 
for change in colour, shape and drug content.
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